Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Published

Journal Article

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

Full Text

Duke Authors

Cited Authors

  • Tempero, MA; Arnoletti, JP; Behrman, SW; Ben-Josef, E; Benson, AB; Casper, ES; Cohen, SJ; Czito, B; Ellenhorn, JDI; Hawkins, WG; Herman, J; Hoffman, JP; Ko, A; Komanduri, S; Koong, A; Ma, WW; Malafa, MP; Merchant, NB; Mulvihill, SJ; Muscarella, P; Nakakura, EK; Obando, J; Pitman, MB; Sasson, AR; Tally, A; Thayer, SP; Whiting, S; Wolff, RA; Wolpin, BM; Freedman-Cass, DA; Shead, DA; National Comprehensive Cancer Networks,

Published Date

  • June 1, 2012

Published In

Volume / Issue

  • 10 / 6

Start / End Page

  • 703 - 713

PubMed ID

  • 22679115

Pubmed Central ID

  • 22679115

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Language

  • eng

Conference Location

  • United States